Long-tErm Follow-uP of antithrombotIc Management Patterns In Acute CORonary Syndrome Patients in Asia (EPICOR ASIA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01361386
First received: May 23, 2011
Last updated: June 13, 2014
Last verified: June 2014
  Purpose

The purpose of this study is to describe the short-and long-tern (i.e. up to 2 years following the index event) AMPs in patients hospitalized for an acute coronary syndrome (i.e. STEMI or NSTE-ACS), and to document clinical outcomes, economic aspects and impact on quality of life of these AMPs in a 'real-life' setting.


Condition
Acute Coronary Syndrome

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long-Term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Asia

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • short- and long-term medication and treatment prescribed by physicians in real-life setting [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • clinical outcome (Cardiovascular events) [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
  • cost of hospitalization [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
  • quality of life (EQ-5D questionnaire) [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]

Enrollment: 13011
Study Start Date: June 2011
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Asian patients hospitalized for ACS within 48 hours of symptom onset and who have a final diagnosis of unstable angina (UA), STEMI or non-ST-segment elevation myocardial infarction (NSTEMI).

Criteria

Inclusion Criteria:

  • Written informed consent has been provided.
  • Diagnosis of STEMI, NSTEMI or UA
  • Hospitalization for the first time within 48 hours of onset of symptoms.

Exclusion Criteria:

  • UA, STEMI, NSTEMI precipitated by or as a complication of surgery, trauma, or GI bleeding or post-PCI UA, STEMI and NSTEMI occurring in patients already hospitalized for other reasons.
  • Current participation in a randomised interventional clinical trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01361386

  Show 109 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Guy Yeoman AstraZeneca
Study Chair: Prof. Huo Yong Peking University 1st Hospital
Study Chair: Jayanti Visvanathan AstraZeneca
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01361386     History of Changes
Other Study ID Numbers: NIS-CAP-XXX-2011/1
Study First Received: May 23, 2011
Last Updated: June 13, 2014
Health Authority: Vietnam: Ministry of Health

Keywords provided by AstraZeneca:
Long-term follow up
Antithrombotic management patterns
Acute Coronary Syndrome
Asia
quality of life

Additional relevant MeSH terms:
Syndrome
Acute Coronary Syndrome
Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Angina Pectoris
Vascular Diseases
Chest Pain
Pain
Signs and Symptoms

ClinicalTrials.gov processed this record on September 18, 2014